Rating Change
HC Wainwright & Co. reiterated its Buy rating on Cogent Biosciences, Inc. Common Stock (NASDAQ:COGT) on November 09, 2026.
reiterateNASDAQ:COGT
HC Wainwright & Co. Reiterates Buy Rating on Cogent Biosciences, Inc. Common Stock (COGT)
HC Wainwright & Co. reiterated its Buy rating on Cogent Biosciences, Inc.
At publication ·
What changed
Cogent Biosciences, Inc. Common Stock (NASDAQ:COGT) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $32.88
- Market capitalization
- $5.7B
At a glance
Key takeaways
- HC Wainwright & Co. maintained a Buy rating on Cogent Biosciences (COGT) on November 9, 2026, as the stock trades at $32.88 with a $5.7B market cap.
Market Context
Cogent Biosciences, Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $32.88 with a market capitalization of $5.7B. The stock has gained 119.5% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Cogent Biosciences, Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Cogent Biosciences, Inc. Common Stock
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 09, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 16, 2026 | Wedbush | Outperform | N/A |
| Sep 15, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 17, 2026 | Piper Sandler | Overweight | N/A |
| Aug 12, 2026 | Guggenheim | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View COGT Stock Page
Frequently Asked Questions
What does the Buy rating mean for COGT?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Cogent Biosciences, Inc. Common Stock (NASDAQ:COGT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the COGT forecast page.